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Introduction 
 
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder, 
characterized by intensely itchy eczema. The prevalence of AD has tripled within 
the last three decades, currently affecting up to 30% of children and 10% of 
adults in industrial countries 1. The pathogenesis of AD is not fully understood. 
Besides some other environmental factors, the skin microbiome - the community 
of microorganisms colonizing the skin - has been attributed a pathogenic role in 
AD. The altered skin colonization with microorganisms in AD patients versus 
healthy individuals has been extensively investigated for bacteria, in particular 
Staphylococcus aureus. These aspects are highlighted in the chapter of 
Infectious Complications in Atopic Dermatitis by Peck Y Ong in this issue. 
Recently, microbiome research extended on the possible pathogenic role of fungi 
in AD. This research has been focused on the commensal lipophilic yeast 
Malassezia spp. because (i) AD patients are more frequently sensitized to 
Malassezia spp. than healthy individuals, and (ii) AD patients may benefit from an 
antifungal therapy that is effective against Malassezia spp. This led to the 
publication of a plethora of studies on the possible role of Malassezia spp. in the 
development and course of AD. Several studies applied culture or molecular 
methods such as polymerase chain reaction to assess possible differences in the 
epidemiology of Malassezia spp. skin colonization between healthy and diseased 
skin such as AD. However, these studies obtained variable results presumably 
owing to methodical inconsistencies such as skin sampling from inconsistent 
body sites and the use of different cultivation methods or PCR primers. Next 
generation sequencing is a molecular method that has been recently introduced 
into skin microbiome research, as it gives information on skin microbial 
communities that is complementary to cultivation or PCR. As for the bacterial skin 
microbiome, next generation sequencing revealed that the skin fungal 
microbiome is highly specific for a particular body site 2. Therefore, comparing 
the prevalence of Malassezia species between different body sites sampled in 
different studies will give unreliable results. Also, the epidemiological studies 
used different culture media to detect Malassezia species. We [unpublished data] 
and others have shown that different culture media favor the growth of particular 
Malassezia species 3-6. Therefore, the use of only one or a few types of culture 
media does not necessarily depict the whole spectrum of Malassezia species 
present in a sample. Surprisingly, studies comparing healthy individuals and AD 
patients did not reveal a difference in the frequency of skin colonization with 
Malassezia spp. between both groups 6. It therefore appears as a medical 
conundrum how Malassezia spp. on the one hand seems to contribute to the 
pathogenesis of AD patients and on the other hand is a commensal on healthy 
skin. Recent research at least partially elucidated the possible pathogenetic role 
of Malassezia spp. in AD. 
 
 
Epidemiology 
The skin is an ecosystem and harbors diverse and body site-specific microbial 
communities, which have been termed the skin microbiome. The phylogenetic 
profiling of the skin microbiome revealed that fungi are part of the normal skin 
flora at all body sites and comprise 1-22% of the phylogenetic composition of the 
skin microbiome 7. Malassezia spp. almost exclusively comprises to the fungal 
flora of the healthy skin on most body sites. It is therefore the main eukaryotic 
member of the microbial flora of the skin 6, 7. Malassezia spp. is a genus of 
lipophilic yeasts (Figure 1). Most of the Malassezia species lack the genes for 
fatty acid synthase genes and therefore rely on exogenous fatty acid sources to 
satisfy their nutritive requirement 8. M. pachydermatis, a species isolated from 
dogs and other animals 9, is the only known Malassezia species that grows in the 
absence of exogenous lipids 8. Their need for exogenous lipids explains the 
pedilection of Malassezia species for seborrheic skin sites, such as the head and 
neck. The taxonomy of Malassezia spp. has been defined in its current form in 
1996, based on morphology, ultrastructure, physiology and molecular biology 10. 
The genus Malassezia spp. belongs to the phylum Basidiomycota and currently 
encompasses 14 species that have been isolated from human and animal skin 
(Table 1). Two of these species, M. globosa and M. restricta, are consistently 
found on healthy skin of individuals from the U.S. and Europe, and are identified 
on almost all body sites 2, 6. However, epidemiological studies indicated a 
geographical variation in the distribution of particular Malassezia species, 
presumably owing to climate factors. For example, M. sympodialis has been 
reported in studies from Canada, Russia and Sweden as the most frequent 
species, whereas in Japan M. furfur was the most common species 6. 
 
Table 1. Currently identified Malassezia species (modified from 11-13) 
Malassezia species Isolated from 
human skin 
Isolated from 
animal skin 
Description as 
species (year) 
M. caprae  X 2007 
M. cuniculi  X 2011 
M. dermatis X  2002 
M. equina  X 2007 
M. furfur X X 1889 
M. globosa X X 1996 
M. japonica X  2003 
M. nana  X 2004 
M. obtusa X  1996 
M. pachydermatis  X 1925 
M. restricta X  1996 
M. slooffiae X X 1996 
M. sympodialis X X 1990 
M. yamatoensis X  2004 
 
 
 
Risk factors for sensitization to Malassezia spp. 
 
Sensitization to Malassezia spp. may correlate with the severity of atopic 
dermatitis 
As Malassezia spp. is part of the healthy skin flora, it appears reasonable that it 
regularly interacts with skin immune cells such as dendritic cells or lymphocytes. 
Accordingly, Malassezia spp.-specific IgG and IgM antibodies can be regularly 
detected in healthy individuals 8. In contrast, the rate of IgE-mediated 
sensitization to Malassezia spp. is very low or even absent among individuals 
with healthy skin. In contrast, a high proportion of AD patients appears sensitized 
to this yeast 14, as demonstrated by positive skin prick tests in up to 80% of adult 
AD patients 15-18. Because skin test extracts for Malassezia spp. are not yet 
commercially available and standardized it is nearly impossible to compare the 
results of different skin prick test studies. Therefore, the detection of Malassezia 
spp.-specific serum IgE is desirable to assess sensitization. Fortunately, a 
standardized kit (ImmunoCAP® m70, Phadia) for the detection of Malassezia 
spp.-specific serum IgE is available, which is based on the ATCC strain 42132. 
Recently, a new test kit (ImmunoCAP® m227) has been introduced which 
contains the antigens of several Malassezia spp. and therefore is very sensitive 
19. Using these commercial kits, Malassezia spp.-specific IgE are found in up to 
one third of children 15, 20-22 and two thirds of adults with AD 15, 19, 22-24. 
Accordingly, a recent study on 176 adult AD patients found higher rates of IgE-
mediated Malassezia sensitization among patients with severe compared to 
moderate AD 25. These high rates of Malassezia spp.-specific IgE detection in 
adult AD patients are consistent with the rates of positive Malassezia spp. skin 
prick tests in this population (see above). Interestingly, sensitization rates against 
Malassezia spp. are particularly higher in patients with head and neck type of AD 
19. This may be attributed to the lipophilic properties and hence the predilection of 
this yeast for seborrheic skin areas such as the head and neck region. Therefore 
some authors assume that Malassezia spp. plays a pathogenic role particularly in 
this clinical subtype of AD 26. 
 
Pathophysiology 
The pathophysiologic mechanisms underlying this high frequency of Malassezia 
spp.-sensitization in AD patients compared to healthy individuals remain to be 
elucidated. It appears, that several endogenous factors such as the dysfunctional 
skin barrier or aberrations in the skin immune system of AD patients, as well as 
environmental factors influence the skin colonization with Malassezia spp. and 
the IgE-mediated sensitization to this yeast 27. This sensitization to Malassezia 
spp. may correlate to the severity of AD particularly in adults as recently shown in 
two studies on 132 children and 128 adults with AD 22 28. The lower frequency of 
Malassezia spp. sensitization in children compared to adults and therefore the 
missing correlation between AD severity and Malassezia spp.-specific IgE in 
children might owe to the poor growth conditions for Malassezia spp. in children 
compared to adults. Children produce low amounts of sebum in their skin, and 
sebum production increases during puberty and is high until the age of 50 29. 
Hence, the growths conditions for Malassezia spp. on pediatric skin are worse 
than on adult skin, and this could be the reason that sensitization to Malassezia 
spp. preferably occurs in adulthood 22. Several allergens of Malassezia spp. 
elucidate a specific IgE response. To date, at least 14 allergens of three 
Malassezia species, namely M. furfur, M. sympodialis and M. globosa, are 
characterized on a molecular basis 30 (Table 2), and 13 of these allergens are 
listed in the official allergen nomenclature list (http://www.allergen.org). These 
allergens may be released to a higher amount in the environment of atopic skin. 
For example, the allergen Mala s 12, is released in an higher amount at pH 6.0 
that represents conditions of atopic skin, than in the more acidic environment of 
pH 5.5 of healthy skin 31. It remains unclear if the IgE response plays a 
pathogenic role in AD or rather serves as a marker for the severity of AD, but the 
some possible mechanisms how Malassezia spp. allergens induce inflammation 
in atopic skin have been elucidated in recent years and are described in the 
following. 
 Table 2. Allergens from Malassezia species and their relevance in atopic dermatitis  
Allergen Source Mass 
(kDa) 
Function Sensitization (%) Comment Ref 
Mala f 2 M. furfur 21 Peroxysomal 
membrane 
protein 
72  32 
Mala f 3 M. furfur 20 Peroxysomal 
membrane 
protein 
70  32 
Mala f 4 M. furfur 35 Mitochondrial 
malate 
dehydrogenase 
83  33 
Mala s 1 M. sympodialis 36  unknown  34 
Mala s 5 M. sympodialis 19  unknown  35 
Mala s 6 M. sympodialis 18 Cyclophilin 92%  35, 36 
Mala s 7 M. sympodialis 22  40-60  35, 37 
Mala s 8 M. sympodialis 16  40-72  35, 37 
Mala s 9 M. sympodialis 11  24-36  35, 37 
Mala s 10 M. sympodialis 86 Heat shock 
protein70 
69  38 
Mala s 11 M. sympodialis 23 Manganese 
superoxide 
dismutase 
43-75 Induces dendritic cell maturation, 
release of IL-6, IL-8, IL-12p70, 
TNF-α by dendritic cells, auto-
reactive T cells against human 
39-42 
homologe 
Mala s 12 M. sympodialis 67 Glucose-
methanol-choline 
oxidoreduktase 
62  43 
Mala s 13 M. sympodialis 13 Thioredoxin 50 Induces auto-reactive T cells 
against human homologe,  
44, 45 
MGL_1304 M. globosa 17  62 Induces degranulation of mast 
cells, IL-4 release by basophils 
46, 47 
 Malassezia spp. interacts with the skin immune system 
Prior studies indicated that Malassezia spp. interacts with various types of human 
skin and immune cells. This induces a pro-inflammatory immune response by 
these immune cells, which seems to contribute to the inflammation during AD 
flares. It is still unclear how the interaction between Malassezia spp. cells and 
host cells occur, but some different mechanisms have been postulated. First, 
Malassezia spp. penetrated the impaired skin barrier, which is typical for AD 
patients. In the epidermis and dermis, Malassezia spp. is recognized by 
keratinozytes and immune cells such as Langerhans cells, dermal dendritic cells, 
natural killer cells and fibroblasts 48. A second possible mechanism of Malassezia 
spp. – human cell interaction might be mediated by proteins of Malassezia spp. 
that are packed and released in nanovesicles 49. It was demonstrated that these 
nanovesicles stimulate dendritic cells and mast cells to release of TNF-alpha, IL-
6, IL-8, IL-10 and IL-12p70 40, 50. These cytokines may contribute to skin 
inflammation in AD. Some other authors suggest that Toll-like receptors (TLRs) 
such as TLR2 recognize Malassezia spp. 51. TLRs are members of the large 
family of pattern recognition receptors, which play a key role in the innate 
immune system as they recognize molecules that are commonly shared by 
pathogens.Some recent findings substantiated the relevance of TLRs for the 
immune response of human cells against Malassezia spp. For example, 
Malassezia spp. induces the expression of TLR2 and TLR4 on human 
keratinocytes 52 and human dendritic cells 48, inducing the production human beta 
defensin 2 and CXLC8 53 (Figure 2). Another possible mechanism could be the 
activation of the NLRP3 inflammasome in skin dendritic cells by Malassezia spp. 
This leads to the release of pro-inflammatory cytokines such as production of IL-
1beta, and IL-4, IL-5, IL-13 which a key players in the pathogenesis of AD 54-56 
(Figure 2). 
We have above mentioned the IgE-mediated sensitization to various Malassezia 
spp. allergens. These allergens may also directly stimulate IgE-independent 
immune mechanisms. For example, Mala s 13 is a fungal thioredoxin that is very 
similar to its human counterpart (Figure 3). When human CD4+ T cells recognize 
the fungal thioredoxin they may cross-react to the human enzyme which is 
expressed by human keratinocytes. This will induce a T cell-mediated skin 
inflammation, which is commonly seen in AD 45. A similar induction of 
autoreactive T cells and T cell-mediated inflammation was observed for another 
Malassezia spp. allergen, Mala s 11, which is a manganese-dependent 
superoxide dismutase. The significance of these allergens for skin inflammation 
in AD were substantiated by the strong correlation between AD severity and Mala 
s 11 sensitization 41. 
Management and therapeutic approaches with antifungals in AD 
The basis of every effective AD therapy is the use of skin emollients. They 
rehydrate the skin and repair the impaired skin barrier. In case of clinically 
manifest skin inflammation during AD flares, an anti-inflammatory treatment is 
necessary. This most commonly requires topical steroids or calcineurin inhibitors. 
Another promising therapeutic approach is the identification and elimination of 
trigger factors such as Malassezia spp. 27, for example by an anti-fungal therapy. 
The usefulness of an antifungal therapy for AD has been discussed since many 
years. Azole antifungals are the most common class of antifungal drugs 
prescribed for AD patients. In vitro, azole antifungals are effective against 
Malassezia spp. 29, 57 but susceptibility testing of M. pachydermatis, a species 
most commonly isolated from dogs, showed that strains isolated from dogs with 
AD were less susceptible to azole antifungals than strains isolated from healthy 
dogs 58. In humans, the resistance of Malassezia spp. to antifungals has not 
been investigated to date. 
Several trials investigated the effects of topical or systemic azole 
antifungals on AD patients and compared it to placebo. However, these trials 
gave somehow ambiguous results. As a clinical experience, the topical 
application of ketoconazole on the face of patients with AD of the head and neck 
type improves eczema. However, in a placebo-controlled study the combination 
of topical miconazole-hydrocsortisone cream with ketoconazole shampoo was 
not superior to hydrocortisone alone in patients with head and neck type AD 59. 
The benefit of a systemic antifungal treatment for AD patient has been 
investigated in a randomized, placebo controlled trial on 36 AD patients treated 
with ketoconazole versus 39 AD patients treated with placebo. AD severity 
improved significantly in the ketoconazole group but not in the placebo group 60. 
For another trial, a total of 53 AD patients were treated with either two different 
dosages of itraconazole or placebo. The improvement of AD severity was 
significantly higher in itraconazole treated patients than in the placebo group 61. 
The positive effect of azole antifungals on AD could also owe to the anti-
inflammatory properties of ketoconazole or itraconazole, as these drugs inhibit 
the production of IL-4 and IL-5 by T cells 62. 
The positive effects of antifungals were not confirmed by another study on 15 AD 
patients treated with ketoconazole versus 14 AD patients treated with placebo. 
Both treatment groups received topical steroids. Although AD severity improved 
in both treatment groups, this improvement was not correlated to ketaconazole 
but rather to the topical steroids 63. The ambiguous results of these clinical trials 
might be attributed to a selection bias and low patient numbers. It can be 
speculated that antifungal therapies are more effective in a particular subgroup of 
AD, for example in patients with a head-neck type of eczema. More recently 
published studies were of less quality, for example they comprised retrospective 
observations and lacked a standardized scoring system to assess the severity of 
AD 64. More randomized, placebo controlled studies on large patient populations 
are needed to reliably assess the benefit of an antifungal therapy in AD. 
In summary, there is little doubt that Malassezia spp. plays a role in AD as it may 
interact with the local skin immune responses and barrier function and 
sensitization against this skin-colonizing yeast can correlate with disease activity; 
also antifungal therapy shows beneficial effects in some patients. However the 
pathogenetic mechanism and mutual interaction between Malassezia spp. and 
AD still remain partly unclear and need further investigations.   
Figure legends 
Figure 1. 
Malassezia sympodialis culture isolated from a patient with atopic dermatitis. On 
Malassezia CHROMagar, grown for 72 hours at 32 °C. (With permission from 65) 
 
Figure 2. 
Proposed mechanisms by which Malassezia spp. contributes to skin 
inflammation in atopic dermatitis (AD) patients. The increased pH in atopic skin 
contributes to increased allergen release by Malassezia spp. These allergens, 
supposedly together with whole Malassezia spp. cells, penetrate the epidermis 
through the disturbed skin barrier in AD patients. Malassezia spp. cells and their 
allergens may be recognized by toll-like receptor 2 expressed on keratinocytes 
and dendritic cells what elicits the release of pro-inflammatory cytokines. 
Malassezia spp. components elicit the production of Malassezia spp.-specific IgE 
antibodies through the dendritic cell and T cell-mediated activation of B cells. 
These IgE antibodies may also contribute, possibly through mast cells, to the 
inflammation in atopic skin. Finally, autoreactive T cells can cross react between 
fungal and human manganese-dependent superoxide dismutase (MgSOD) and 
hence sustain skin inflammation. (With permission from 65) 
 
Figure 3. 
Crystal structure of the Malassezia sympodialis thioredoxin Mala s 13 (Courtesy 
Prof. Reto Crameri, Davos, Switzerland) 
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